Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide plus aspiration sclerotherapy for dominant hepatic cysts
NL-OMON40608Phase 3Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatic cyst comparing Pasireotide + aspiration sclerotherapy with Placebo + aspiration sclerotherapy (2 arms). Primary endpoint: Proportional change in cyst diameter at 4 weeks. Started Apr 2014; status: active, not recruiting.
02
Drugs
pasireotide LAR
03
Conditions
hepatic cyst
Beyond the preview
Go deeper on NL-OMON40608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40608.